Elevated serum concentration of interleukin-1 receptor antagonist (IL- 1ra) is correlated to interleukin-6 and to hypoalbuminemia in cachectic patients with colorectal cancer

被引：8

作者：

Shibata M. ^{[1
]}

Nagata Y. ^{[1
]}

Kimura T. ^{[1
]}

Kanou H. ^{[1
]}

Nezu T. ^{[1
]}

Takekawa M. ^{[1
]}

Fukuzawa M. ^{[1
]}

机构：

[1] First Department of Surgery, Nihon University, School of Medicine, Tokyo 173-0032, 30-1 Oyaguchi-kamimachi, Itabashi-ku

来源：

International Journal of Clinical Oncology | 2000年 / 5卷 / 2期

关键词：

Cachexia; Colorectal cancer; Interleukin-1 receptor antagonist; Interleukin-6;

D O I：

10.1007/s101470050101

中图分类号：

学科分类号：

摘要：

Background. The mechanisms leading to the development of cancer cachexia are still not well understood. Some important factors, including cytokines and growth factors, are involved, and recently, cytokines such as interleukin-1 and interleukin-6 have been reported to be involved as mediators of this disorder. Methods. In patients with colorectal cancer, serum concentrations of interleukin-1 receptor antagonist (IL-1ra) and interleukin-6 (IL-6) were measured by enzyme-linked immunosorbent assay (ELISA) and analyzed in relation to the patient's nutrition (in terms of albumin concentration [percentage of total protein] in the serum) and the tumor load. Results. The concentration of IL-1ra was significantly increased in cachectic patients compared with that in healthy volunteers and in the non-cachectic patients, and the concentration was correlated to the serum concentration of IL-6 and inversely correlated to the concentration of albumin (%). These concentrations, however, did not correlate to levels of tumor markers tested, ie, carcinoembryonic antigen (CEA) and carbohydrate antigen (CA)19-9. Conclusion. It was shown that the serum concentration of IL-1ra was a useful indicator for cancer cachexia and hypoalbuminemia; IL-1ra seems to be produced by immune-regulating host cells rather than by neoplastic cells.

引用

页码：116 / 120

页数：4

共 25 条

[21]

Lonnroth C., Moldawer L.L., Gelin J., Et al., Tumor necrosis factor alpha and interleukin-1 alpha production in cachexic, tumor-bearing mice, Int J Cancer, 46, pp. 889-896, (1990)

[22]

Oliff A., The role of tumor necrosis factor (cachectin) in cachexia, Cell, 54, pp. 141-151, (1988)

[23]

Beutler B., Greenwalt D., Humes J.D., Identity of tumor necrosis factor and the macrophage-secreted factor cachectin, Nature, 316, pp. 552-555, (1985)

[24]

Cerami A., Ikeda Y., Le Trang N., Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: The role of cachectin (tumor necrosis factor), Immunol Lett, 11, pp. 173-181, (1985)

[25]

Langstein H.N., Doherty G.M., Fraker D.L., Et al., The roles of gamma interferon and tumor necrosis factor alpha in an experimental rat model of cancer cachexia, Cancer Res, 51, pp. 2302-2311, (1991)

← 1 2 3 →